[{"id":"6e723a13-4912-4048-8073-6e3f7a645994","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441475","created_at":"2022-09-26T15:56:05.332Z","updated_at":"2024-07-02T16:36:03.502Z","phase":"Phase 2","brief_title":"A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients","source_id_and_acronym":"NCT05441475","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 overexpression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • irpagratinib (ABSK011)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 10/10/2024","study_completion_date":" 10/10/2024","last_update_posted":"2022-09-26"},{"id":"aba6b3e5-cb1f-46a6-86b7-19b8fd3e71e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906434","created_at":"2021-05-28T13:52:37.440Z","updated_at":"2024-07-02T16:36:08.012Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04906434","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 overexpression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irpagratinib (ABSK011)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2022-06-30"}]